Toronto Dominion Bank Reduces Holdings in DaVita Inc. (NYSE:DVA)

Toronto Dominion Bank reduced its stake in DaVita Inc. (NYSE:DVA) by 47.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,781 shares of the company’s stock after selling 14,187 shares during the period. Toronto Dominion Bank’s holdings in DaVita were worth $2,179,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Newbridge Financial Services Group Inc. purchased a new position in shares of DaVita in the fourth quarter valued at about $30,000. Principal Securities Inc. purchased a new stake in DaVita in the 4th quarter worth approximately $37,000. GAMMA Investing LLC purchased a new position in shares of DaVita during the fourth quarter valued at approximately $60,000. Quent Capital LLC raised its holdings in shares of DaVita by 21.0% during the first quarter. Quent Capital LLC now owns 581 shares of the company’s stock valued at $80,000 after acquiring an additional 101 shares in the last quarter. Finally, Quest Partners LLC purchased a new stake in DaVita in the fourth quarter worth $74,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Insider Transactions at DaVita

In related news, Director Barbara J. Desoer sold 5,030 shares of the stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $138.81, for a total transaction of $698,214.30. Following the transaction, the director now owns 10,954 shares in the company, valued at $1,520,524.74. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 2.00% of the company’s stock.

DaVita Trading Down 3.6 %

Shares of NYSE DVA opened at $137.41 on Friday. The company has a market cap of $12.05 billion, a PE ratio of 15.61, a P/E/G ratio of 1.05 and a beta of 0.87. The company has a debt-to-equity ratio of 7.95, a quick ratio of 1.37 and a current ratio of 1.43. The firm’s 50 day moving average price is $140.63 and its 200-day moving average price is $131.37. DaVita Inc. has a 52-week low of $71.51 and a 52-week high of $147.93.

DaVita (NYSE:DVA) last issued its earnings results on Thursday, May 2nd. The company reported $2.38 EPS for the quarter, beating the consensus estimate of $1.95 by $0.43. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The business had revenue of $3.07 billion for the quarter, compared to the consensus estimate of $3.03 billion. During the same period last year, the business posted $1.58 EPS. The company’s revenue was up 6.9% compared to the same quarter last year. On average, equities research analysts expect that DaVita Inc. will post 9.62 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. TD Cowen upped their price objective on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday. Barclays lifted their price target on shares of DaVita from $133.00 to $150.00 and gave the company an “equal weight” rating in a research report on Monday, May 6th. StockNews.com cut shares of DaVita from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 8th. Finally, Truist Financial lifted their target price on shares of DaVita from $135.00 to $150.00 and gave the company a “hold” rating in a report on Wednesday, May 15th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, DaVita presently has a consensus rating of “Hold” and a consensus price target of $146.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.